Global Urinary Tract Infection Market Size, Share & Trends Analysis Report By Test Type (Biochemical Urinary Tract Infection, Microscopic Urinary Tract Infection, Flow Cytometric Urinary Tract Infection) By Indication (Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection, Neurogenic Bladder Infections), End-User (Hospitals & Clinics, and Home Healthcare) Forecast Period 2022-2028
The global urinary tract infection market is anticipated to grow at a CAGR of around 4.8% during the forecast period. Urinary tract infections affect the urinary tract of a person also causing bladder (cystitis), urethra (urethritis), or kidney infections. Urinary tract infections are developed when microbes enter the urinary tract and result in infection. Bacteria are considered to be the most common cause of urinary tract infection, coli bacteria that live in the bowel causes most urinary tract infections. The number of cases of urinary tract infection increases as the incidence of diabetes and kidney stones rises, which in turn raises drug demand, driving the global urinary tract infection market. Moreover, the demand for urinary tract infections treatment drugs is expected to grow due to the introduction of more effective combination drugs and the growing geriatric population.
With an increase in the number of cases of adverse drug reactions (ADRs) being identified across the globe, there is a lack of public awareness for drug adoption, which is a major restraint for the urinary tract infection industry. Further, COVID-19 has also a certain positive impact on the market such as some of the common comorbidity seen in COVID-19 patients in diabetes, hypertension, and chronic lung disease. Not only respiratory illness however COVID-19 may also damage certain organs systems of the body along with human urinal systems. Therefore COVID-19 may result in the cause of bladder dysfunction and further projected to propel the demand for drugs during the forecast period.
The global urinary tract infection market is segmented based on test type, indication, and end-user. On the basis of test type, the market is segmented into biochemical urinary tract infection, microscopic urinary tract infection, and flow cytometric urinary tract infection. Based on indication, the market is segmented into complicated urinary tract infection, uncomplicated urinary tract infection, neurogenic bladder infections. Further on the basis of end-user, the market is segmented into hospitals & clinics, and home healthcare.
Global Urinary Tract Infection Market Share by Indication, 2020 (%)
Global Urinary Tract Infection Market Share by Indication
Complicated urinary tract infection projected to hold a significant share in the global urinary tract infection market
Among indication, the complicated urinary tract infection segment is projected to have a considerable share in the global market. Due to the rise in drug-resistant bacteria and the overuse of antibiotics, the prevalence of complicated urinary tract infection is projected to rise in the future. Quinolones are prescribed by most doctors to treat complex urinary tract infection cases. Cephalosporin is the second most prescribed antibiotic for complicated urinary tract infections. Complicated urinary tract infections have a higher chance of medication failure, requiring longer antibiotic courses and, in certain cases, further testing. Complicated urinary tract infections may occur in males, pregnant women, in immunocompromised patients, or the elderly, due to atypical bacteria, after instrumentation or in combination with medical equipment such as urinary catheters, in renal transplant patients, and patients with impaired renal function. Overall, the prevalence of complicated urinary tract infection is expected to rise during the forecast period, owing to rising bacterial resistance in urinary tract infection cases and a higher recurrence rate.
The global urinary tract infection market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Due to a high prevalence rate of urinary tract infections, North America is projected to have a significant share in the global market. Furthermore, the region has a well-developed healthcare system, which contributes to the market share. According to National Center for Biotechnology Information in 2019, in the US the prevalence of urinary tract infection in women above 65 years is approximately 20.0% as compared to 11.0% prevalence in the overall population, therefore almost 50.0% to 60.0% of adult women will have at least one urinary tract infection in their life.
Global Urinary Tract Infection Market Growth, by Region 2022-2028
Global Urinary Tract Infection Market Share by region
Asia-Pacific is projected to grow significantly in the global urinary tract infection market during the forecast period.
Geographically, Asia-Pacific estimated to have considerable CAGR in the global urinary tract infection market during the forecast period. The growth is attributed to the increasing prevalence of chronic diseases such as diabetes and renal failure in major countries such as China, India, and. The other factors being increasing large number of drug manufacturers for the disease, increasing awareness among the people regarding the treatment options for urinary tract infections, rise inpatient population. Furthermore, the demand for urinary tract infection treatment drugs in private hospitals and further projected to provide ample opportunity to the market growth.
Market Players Outlook
The key players of the urinary tract infection market include AstraZeneca PLC, Bayer AG, Danaher Corp., Becton, Dickinson and Co., Biotronik SE & Co. KG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Siemens AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in November 2019, Shionogi & Co., Ltd. got the US FDSA approval for its Fetroja that is an antibacterial drug for treatment for patients 18 years and above with complicated tract infections including kidney infections. This approval will be providing an additional treatment option for patients with complicated urinary tract infection who have limited and no treatment options.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Urinary Tract Infection market
- Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying 'who-stands-where in the market.
Table of Contents
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Urinary Tract Infection Industry
- Recovery Scenario of Global Urinary Tract Infection Industry
1.2.1. By Segments
1.2.2. By Geography
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players
5.1.1. Biochemical Urinary Tract Infection
5.1.2. Microscopic Urinary Tract Infection
5.1.3. Flow Cytometric Urinary Tract Infection
5.2. Global Urinary Tract Infection market by Indication
5.2.1. Complicated Urinary Tract Infection
5.2.2. Uncomplicated Urinary Tract Infection
5.2.3. Neurogenic Bladder Infections
5.3. Global Urinary Tract Infection market by End-User
5.3.1. Hospitals and Clinics
5.3.2. Home Healthcare
6.1.1. United States
6.2.6. Rest of Europe
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7.2. ARKRAY Group
7.3. AstraZeneca PLC
7.4. Bayer AG
7.5. Danaher Corp.
7.6. Becton, Dickinson and Co.
7.7. Biomerieux S.A.
7.8. Bio-Rad Laboratories Inc.
7.9. Biotronik SE & Co. KG
7.10. Boehringer Ingelheim GmbH
7.11. F. Hoffmann-La Roche Ltd.
7.12. GlaxoSmithKline PLC
7.13. Novartis International AG
7.14. Pfizer Inc.
7.15. Sanofi S.A.
7.16. Siemens AG
7.17. Shionogi & Co., Ltd.
7.18. Sysmex Europe GmbH.
7.19. Teva Pharmaceutical Industries Ltd.
7.20. Watson’s Personal Care Pte. Ltd.
A selection of companies mentioned in this report includes:
- Acon Laboratories, Inc.
- ARKRAY Group
- AstraZeneca PLC
- Bayer AG
- Danaher Corp.
- Becton, Dickinson and Co.
- Biomerieux S.A.
- Bio-Rad Laboratories Inc.
- Biotronik SE & Co. KG
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- Novartis International AG
- Pfizer Inc.
- Sanofi S.A.
- Siemens AG
- Shionogi & Co., Ltd.
- Sysmex Europe GmbH.
- Teva Pharmaceutical Industries Ltd.
- Watson’s Personal Care Pte. Ltd.